AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNFA
  4. [D] TNF Pharmaceuticals, Inc. SEC Filing

[D] TNF Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D
Rhea-AI Filing Summary

TNF Pharmaceuticals, Inc. filed a Form D reporting a Regulation D, Rule 506(b) exempt offering conducted in 2025 for a total of $7,000,000, of which $7,000,000 was sold and $0 remained. The issuer is a Delaware corporation formed in 2023 with principal offices in New York. The filing lists executive officers and directors, including Mitchell Glass as Chief Medical Officer who signed the notice.

Placement agents received estimated sales commissions of $630,000 and warrants to purchase up to 126,000 shares at a $5.00 exercise price were issued to agents or designees. The offering was not in connection with a business combination, had a $0 minimum outside-investor investment, and lists 12 total investors.

TNF Pharmaceuticals, Inc. ha presentato un Modulo D relativo a un'offerta esente ai sensi del Regulation D, Rule 506(b) condotta nel 2025 per un totale di $7.000.000, interamente sottoscritti ($7.000.000 venduti, $0 residui). L'emittente 猫 una societ脿 del Delaware costituita nel 2023 con sede principale a New York. Nell'inoltro sono indicati dirigenti e amministratori, tra cui Mitchell Glass come Chief Medical Officer, che ha firmato la comunicazione.

Agenti di collocamento hanno ricevuto commissioni di vendita stimate in $630.000 e sono stati emessi ai medesimi o a loro designati warrant per l'acquisto fino a 126.000 azioni a un prezzo di esercizio di $5,00. L'offerta non era connessa a una combinazione aziendale, prevedeva un investimento minimo da investitori esterni di $0 e riporta un totale di 12 investitori.

TNF Pharmaceuticals, Inc. present贸 un Formulario D que informa una oferta exenta bajo el Regulation D, Rule 506(b) realizada en 2025 por un total de $7,000,000, de los cuales se vendieron $7,000,000 y quedaron $0. El emisor es una corporaci贸n de Delaware constituida en 2023 con oficinas principales en Nueva York. La presentaci贸n enumera a los principales ejecutivos y directores, incluido Mitchell Glass como Chief Medical Officer, quien firm贸 la notificaci贸n.

Los agentes colocadores recibieron comisiones de venta estimadas en $630,000 y se emitieron a los agentes o sus designados warrants para comprar hasta 126,000 acciones a un precio de ejercicio de $5.00. La oferta no estuvo relacionada con una combinaci贸n empresarial, ten铆a una inversi贸n m铆nima de inversores externos de $0 y figura con un total de 12 inversores.

TNF Pharmaceuticals, Inc.電� 2025雲勳棎 鞁れ嫓霅� Regulation D, Rule 506(b) 氅挫牅 瓿惦鞐� 雽�頃� 齑濎暋 $7,000,000鞛勳潉 氤搓碃頃橂姅 Form D毳� 鞝滌稖頄堨溂氅�, 鞚� 欷� $7,000,000臧� 氇憪 韺愲Г霅橁碃 $0臧� 雮晿鞀惦媹雼�. 氚滍枆須岇偓電� 2023雲勳棎 靹る霅� 雿鸽澕鞗柎 氩曥澑鞙茧 氤胳偓電� 雺挫殨鞐� 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 鞛勳洂 氚� 鞚挫偓霌れ澊 旮办灛霅橃柎 鞛堨溂氅�, Mitchell Glass臧� Chief Medical Officer搿滌劀 韱奠靹滌棎 靹滊獏頄堨姷雼堧嫟.

頂岆爤鞚挫姢毹柬姼 鞐愳澊鞝勴姼霌れ潃 於旍爼 韺愲Г 靾橃垬耄� $630,000鞚� 氚涭晿瓿�, 鞐愳澊鞝勴姼 霕愲姅 攴� 歆�氇呾澑鞐愱矊 頄夓偓臧�瓴� $5.00搿� 斓滊寑 126,000欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞗岆煱韸戈皜 氚滍枆霅橃棃鞀惦媹雼�. 鞚� 瓿惦電� 旮办梾瓴绊暕瓿� 甏�霠澊 鞐嗢棃瓿�, 鞕鸽秬 韴瀽鞛� 斓滌唽 韴瀽鞎§潃 $0鞚措┌ 齑� 韴瀽鞛� 靾橂姅 12氇呾溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.

TNF Pharmaceuticals, Inc. a d茅pos茅 un formulaire D d茅clarant une offre exon茅r茅e en vertu du Regulation D, Rule 506(b) r茅alis茅e en 2025 pour un montant total de $7,000,000, dont $7,000,000 ont 茅t茅 vendus et $0 restent. L'茅metteur est une soci茅t茅 du Delaware cr茅茅e en 2023, dont le si猫ge principal est 脿 New York. Le d茅p么t mentionne les dirigeants et administrateurs, y compris Mitchell Glass en tant que Chief Medical Officer, qui a sign茅 l'avis.

Les agents placers ont re莽u des commissions de vente estim茅es 脿 $630,000 et des warrants donnant droit d'acheter jusqu'脿 126,000 actions au prix d'exercice de $5.00 ont 茅t茅 茅mis aux agents ou 脿 leurs d茅sign茅s. L'offre n'茅tait pas li茅e 脿 une op茅ration de fusion-acquisition, pr茅voyait un investissement minimum des investisseurs externes de $0 et compte au total 12 investisseurs.

TNF Pharmaceuticals, Inc. hat ein Form D eingereicht, das ein 2025 durchgef眉hrtes, nach Regulation D, Rule 506(b) befreites Angebot in H枚he von insgesamt $7.000.000 meldet; davon wurden $7.000.000 verkauft und $0 verblieben. Der Emittent ist eine 2023 gegr眉ndete Delaware-Corporation mit Hauptsitz in New York. Die Einreichung nennt F眉hrungskr盲fte und Direktoren, darunter Mitchell Glass als Chief Medical Officer, der die Mitteilung unterzeichnete.

Platzierungsagenten erhielten gesch盲tzte Verkaufsprovisionen von $630.000, und den Agenten oder deren Beauftragten wurden Warrants zum Kauf von bis zu 126.000 Aktien zu einem Aus眉bungspreis von $5,00 ausgestellt. Das Angebot stand nicht im Zusammenhang mit einer Unternehmenszusammenschlie脽ung, sah eine Mindestinvestition externer Investoren von $0 vor und listet insgesamt 12 Investoren.

Positive
  • Completed capital raise of $7.0M provides immediate funding for corporate activities
  • No proceeds paid to named insiders according to the filing
  • Use of Rule 506(b) allowed a private placement to accredited investors without general solicitation
Negative
  • Estimated sales commissions of $630,000 (~9% of proceeds) are relatively high and reduce net proceeds
  • Placement-agent warrants for 126,000 shares at $5.00 introduce potential dilution if exercised
  • Filing does not disclose specific use of proceeds, limiting investor visibility into capital allocation

Insights

TL;DR: Completed $7.0M Rule 506(b) offering with notable underwriting costs and issued placement-agent warrants; modest capital raise for an early-stage pharmaceutical issuer.

The Form D shows a finished private placement under Rule 506(b) raising $7.0 million, with sales commissions estimated at $630,000 representing ~9% of gross proceeds. Issuer granted warrants to placement agents for 126,000 shares at $5.00, which could dilute existing holders if exercised. The offering lists 12 investors and no proceeds paid to named insiders. For investors, key considerations include dilution from warrants and use of proceeds details, which are not specified in the filing.

TL;DR: Governance disclosure is standard for a Form D; officers and directors are identified and no insider payments were reported.

The filing appropriately names executive officers and directors with addresses and roles, and certifies no payments to those individuals from the offering proceeds. The issuer declined to disclose revenue/net asset amounts and indicates formation in 2023, consistent with an early-stage entity. The document provides required regulatory attestations but lacks narrative on intended use of funds, which limits governance transparency regarding capital allocation.

TNF Pharmaceuticals, Inc. ha presentato un Modulo D relativo a un'offerta esente ai sensi del Regulation D, Rule 506(b) condotta nel 2025 per un totale di $7.000.000, interamente sottoscritti ($7.000.000 venduti, $0 residui). L'emittente 猫 una societ脿 del Delaware costituita nel 2023 con sede principale a New York. Nell'inoltro sono indicati dirigenti e amministratori, tra cui Mitchell Glass come Chief Medical Officer, che ha firmato la comunicazione.

Agenti di collocamento hanno ricevuto commissioni di vendita stimate in $630.000 e sono stati emessi ai medesimi o a loro designati warrant per l'acquisto fino a 126.000 azioni a un prezzo di esercizio di $5,00. L'offerta non era connessa a una combinazione aziendale, prevedeva un investimento minimo da investitori esterni di $0 e riporta un totale di 12 investitori.

TNF Pharmaceuticals, Inc. present贸 un Formulario D que informa una oferta exenta bajo el Regulation D, Rule 506(b) realizada en 2025 por un total de $7,000,000, de los cuales se vendieron $7,000,000 y quedaron $0. El emisor es una corporaci贸n de Delaware constituida en 2023 con oficinas principales en Nueva York. La presentaci贸n enumera a los principales ejecutivos y directores, incluido Mitchell Glass como Chief Medical Officer, quien firm贸 la notificaci贸n.

Los agentes colocadores recibieron comisiones de venta estimadas en $630,000 y se emitieron a los agentes o sus designados warrants para comprar hasta 126,000 acciones a un precio de ejercicio de $5.00. La oferta no estuvo relacionada con una combinaci贸n empresarial, ten铆a una inversi贸n m铆nima de inversores externos de $0 y figura con un total de 12 inversores.

TNF Pharmaceuticals, Inc.電� 2025雲勳棎 鞁れ嫓霅� Regulation D, Rule 506(b) 氅挫牅 瓿惦鞐� 雽�頃� 齑濎暋 $7,000,000鞛勳潉 氤搓碃頃橂姅 Form D毳� 鞝滌稖頄堨溂氅�, 鞚� 欷� $7,000,000臧� 氇憪 韺愲Г霅橁碃 $0臧� 雮晿鞀惦媹雼�. 氚滍枆須岇偓電� 2023雲勳棎 靹る霅� 雿鸽澕鞗柎 氩曥澑鞙茧 氤胳偓電� 雺挫殨鞐� 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 鞛勳洂 氚� 鞚挫偓霌れ澊 旮办灛霅橃柎 鞛堨溂氅�, Mitchell Glass臧� Chief Medical Officer搿滌劀 韱奠靹滌棎 靹滊獏頄堨姷雼堧嫟.

頂岆爤鞚挫姢毹柬姼 鞐愳澊鞝勴姼霌れ潃 於旍爼 韺愲Г 靾橃垬耄� $630,000鞚� 氚涭晿瓿�, 鞐愳澊鞝勴姼 霕愲姅 攴� 歆�氇呾澑鞐愱矊 頄夓偓臧�瓴� $5.00搿� 斓滊寑 126,000欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞗岆煱韸戈皜 氚滍枆霅橃棃鞀惦媹雼�. 鞚� 瓿惦電� 旮办梾瓴绊暕瓿� 甏�霠澊 鞐嗢棃瓿�, 鞕鸽秬 韴瀽鞛� 斓滌唽 韴瀽鞎§潃 $0鞚措┌ 齑� 韴瀽鞛� 靾橂姅 12氇呾溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.

TNF Pharmaceuticals, Inc. a d茅pos茅 un formulaire D d茅clarant une offre exon茅r茅e en vertu du Regulation D, Rule 506(b) r茅alis茅e en 2025 pour un montant total de $7,000,000, dont $7,000,000 ont 茅t茅 vendus et $0 restent. L'茅metteur est une soci茅t茅 du Delaware cr茅茅e en 2023, dont le si猫ge principal est 脿 New York. Le d茅p么t mentionne les dirigeants et administrateurs, y compris Mitchell Glass en tant que Chief Medical Officer, qui a sign茅 l'avis.

Les agents placers ont re莽u des commissions de vente estim茅es 脿 $630,000 et des warrants donnant droit d'acheter jusqu'脿 126,000 actions au prix d'exercice de $5.00 ont 茅t茅 茅mis aux agents ou 脿 leurs d茅sign茅s. L'offre n'茅tait pas li茅e 脿 une op茅ration de fusion-acquisition, pr茅voyait un investissement minimum des investisseurs externes de $0 et compte au total 12 investisseurs.

TNF Pharmaceuticals, Inc. hat ein Form D eingereicht, das ein 2025 durchgef眉hrtes, nach Regulation D, Rule 506(b) befreites Angebot in H枚he von insgesamt $7.000.000 meldet; davon wurden $7.000.000 verkauft und $0 verblieben. Der Emittent ist eine 2023 gegr眉ndete Delaware-Corporation mit Hauptsitz in New York. Die Einreichung nennt F眉hrungskr盲fte und Direktoren, darunter Mitchell Glass als Chief Medical Officer, der die Mitteilung unterzeichnete.

Platzierungsagenten erhielten gesch盲tzte Verkaufsprovisionen von $630.000, und den Agenten oder deren Beauftragten wurden Warrants zum Kauf von bis zu 126.000 Aktien zu einem Aus眉bungspreis von $5,00 ausgestellt. Das Angebot stand nicht im Zusammenhang mit einer Unternehmenszusammenschlie脽ung, sah eine Mindestinvestition externer Investoren von $0 vor und listet insgesamt 12 Investoren.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities
OMB APPROVAL
OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number) Previous Names
None
Entity Type
0001321834
MyMD Pharmaceuticals, Inc.
Akers Biosciences, Inc.
Akers Biosciences Inc
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other (Specify)

Name of Issuer
TNF Pharmaceuticals, Inc.
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
Over Five Years Ago
X Within Last Five Years (Specify Year) 2023
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
TNF Pharmaceuticals, Inc.
Street Address 1 Street Address 2
1185 AVENUE OF THE AMERICAS SUITE 249
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
NEW YORK NEW YORK 10036 856-848-8698

3. Related Persons

Last Name First Name Middle Name
Rhodes Ian
Street Address 1 Street Address 2
1185 Avenue of the Americas Suite 249
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Financial Officer
Last Name First Name Middle Name
Schreiber Christopher
Street Address 1 Street Address 2
1185 Avenue of the Americas Suite 249
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Silverman Joshua
Street Address 1 Street Address 2
1185 Avenue of the Americas Suite 249
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Executive Chairman
Last Name First Name Middle Name
Bernstein Bruce
Street Address 1 Street Address 2
1185 Avenue of the Americas Suite 249
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
White Bill J.
Street Address 1 Street Address 2
1185 Avenue of the Americas Suite 249
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Friscia Stephen
Street Address 1 Street Address 2
1185 Avenue of the Americas Suite 249
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Glass Mitchell
Street Address 1 Street Address 2
1185 Avenue of the Americas Suite 249
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Chief Medical Officer

4. Industry Group

Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
X Pharmaceuticals
Other Health Care
Manufacturing
AG真人官方 Estate
Commercial
Construction
REITS & Finance
Residential
Other AG真人官方 Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
Other

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range
No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
$1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
X Decline to Disclose Decline to Disclose
Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)
X Rule 506(b)
Rule 506(c)
Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2025-09-02 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity Pooled Investment Fund Interests
Debt Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities
X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient
Recipient CRD Number None
GP Nurmenkari Inc. 000153480
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
22 Elizabeth Street
City State/Province/Country ZIP/Postal Code
Norwalk CONNECTICUT 06854
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States		 All States
Foreign/non-US
CONNECTICUT
NEW YORK
Recipient
Recipient CRD Number None
Rodman & Renshaw, LLC 000281264
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
600 Lexington Ave
City State/Province/Country ZIP/Postal Code
New York NEW YORK 10022
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States		 All States
Foreign/non-US
NEW YORK
Recipient
Recipient CRD Number None
H.C. Wainwright & Co., LLC 000000375
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
430 Park Ave 4th Floor
City State/Province/Country ZIP/Postal Code
New York NEW YORK 10022
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States		 All States
Foreign/non-US
NEW YORK

13. Offering and Sales Amounts

Total Offering Amount $7,000,000 USD
or Indefinite
Total Amount Sold $7,000,000 USD
Total Remaining to be Sold $0 USD
or Indefinite

Clarification of Response (if Necessary):

14. Investors

 Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
12

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions $630,000 USD
Estimate
Finders' Fees $0 USD
Estimate

Clarification of Response (if Necessary):

Issuer issued to placement agents (or their designees) warrants to purchase up to 126,000 shares at an exercise price of $5.00 (subject to price-based adjustment) under Section 4(a)(2)

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD
Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date
TNF Pharmaceuticals, Inc. /s/ Mitchell Glass Mitchell Glass Chief Medical Officer 2025-09-05

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

Source:

FAQ

What amount did TNFA raise in the Form D offering?

The filing reports a total offering amount of $7,000,000, with $7,000,000 sold and $0 remaining.

Under which exemption was TNF Pharmaceuticals' offering conducted?

The offering was conducted under Regulation D, Rule 506(b).

How much were sales commissions and were any paid to insiders for TNFA?

Estimated sales commissions were $630,000; the filing indicates $0 of gross proceeds were used to pay listed executive officers, directors, or promoters.

Were any warrants or rights issued in the TNFA offering?

Yes, placement agents (or their designees) were issued warrants to purchase up to 126,000 shares at an exercise price of $5.00 subject to adjustment.

How many investors participated in the TNFA offering?

The filing reports a total of 12 investors who invested in the offering.
Stock TNFA logo
TNF Pharmaceuticals

NASDAQ:TNFA

TNFA Rankings

#6239 Ranked by Market Cap
N/A Ranked by Dividends
#11 Top Gainer

TNFA Latest News

Sep 4, 2025
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
Sep 2, 2025
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
Sep 2, 2025
TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
Aug 28, 2025
TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance
Aug 19, 2025
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

TNFA Latest SEC Filings

Sep 5, 2025
[8-K/A] TNF Pharmaceuticals, Inc. Amends Material Event Report
Sep 2, 2025
[8-K] TNF Pharmaceuticals, Inc. Reports Material Event
Aug 19, 2025
[10-Q] TNF Pharmaceuticals, Inc. Quarterly Earnings Report
Aug 14, 2025
[NT 10-Q] TNF Pharmaceuticals, Inc. SEC Filing

TNFA Stock Data

6.45M
141.68k
0.01%
0.31%
33.22%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
United States
NEW YORK